US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Generate Biomedicines

17.72

+1.609.93%

Post-market: 17.62-0.1000-0.56%19:23 EDT

Volume:2.50M

Turnover:43.13M

Market Cap:2.27B

PE:-5.41

High:17.99

Open:16.67

Low:16.03

Close:16.12

52wk High:18.18

52wk Low:11.00

Shares:128.19M

Float Shares:60.29M

Volume Ratio:2.78

T/O Rate:4.15%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.2762

EPS(LYR):-4.9816

ROE:-81.72%

ROA:-34.63%

PB:4.98

PE(LYR):-3.56

Loading ...

Overview Company News Filings

Generate Biomedicines initiated with a Buy at Guggenheim

Generate Biomedicines initiated with an Overweight at Piper Sandler

Generate Biomedicines initiated with a Buy at Goldman Sachs

Generate Biomedicines Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $24

THOMSON REUTERS

U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco

Generate Biomedicines CEO Michael Nally Acquires Common Shares

Generate Biomedicines Director Jane L Mendillo Acquires Common Shares

Noubar Afeyan, Director, Acquires Generate Biomedicines Common Shares

Generate Biomedicines Adopts Amended and Restated Bylaws

Opening Day: Generate Biomedicines makes public debut

Generate Biomedicines Shares Fall After Nasdaq Debut

MT Newswires Live

Stock Track | Generate Biomedicines Plummets 6.25% Intraday as Stock Debuts Below IPO Price

Generate Biomedicines opens at $15.00, IPO priced at $16.00

Shares of Generate Biomedicines Open at $15 in Their Nasdaq Debut VS $16 IPO Price

THOMSON REUTERS

BUZZ-Flagship-backed Generate Biomedicines set for Nasdaq debut after $400 million IPO

Generate Biomedicines Prices $400 Million Initial Public Offering

MT Newswires Live

NASDAQ TRADE HALT REASON NOT AVAILABLE AT 04:00 AM

AI Biotech Firm Generate Biomedicines Sets IPO at $16 Per Share for Nasdaq Debut

U.S. Biotech Firm Generate Biomedicines Raises $400 Mln in IPO

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/GENB/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"GENB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","market":"US","secType":"STK","nameCN":"Generate Biomedicines","latestPrice":17.72,"timestamp":1787601600000,"preClose":16.12,"halted":0,"volume":2500128,"hourTrading":{"tag":"盘后","latestPrice":17.62,"preClose":17.72,"latestTime":"19:23 EDT","volume":21342,"amount":378155.525964,"timestamp":1787613825519,"change":-0.1,"changeRate":-0.005643,"amplitude":0.043454},"delay":0,"changeRate":0.09925558312655074,"floatShares":60288200,"shares":128192484,"eps":-3.27625,"marketStatus":"Post-Mkt","change":1.6,"latestTime":"08-24 19:26:17 EDT","open":16.67,"high":17.985,"low":16.03,"amount":43127460.512928,"amplitude":0.121278,"askPrice":18,"askSize":290,"bidPrice":17.23,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-3.27625,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1787616000000},"marketStatusCode":4,"adr":0,"listingDate":1772168400000,"exchange":"NASDAQ","adjPreClose":16.12,"preHourTrading":{"tag":"盘前","latestPrice":16.56,"preClose":16.12,"latestTime":"09:28 EDT","volume":377,"amount":6154.609447999999,"timestamp":1787578095129,"change":0.44,"changeRate":0.027295,"amplitude":0.028766},"postHourTrading":{"tag":"盘后","latestPrice":17.62,"preClose":17.72,"latestTime":"19:23 EDT","volume":21342,"amount":378155.525964,"timestamp":1787613825519,"change":-0.1,"changeRate":-0.005643,"amplitude":0.043454},"volumeRatio":2.777096},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GENB\",,,,,undefined,":{"symbol":"GENB","floatShares":60288200,"roa":"-34.63%","roe":"-81.72%","lyrEps":-4.981642,"volumeRatio":2.777096,"shares":128192484,"dividePrice":0,"high":17.985,"amplitude":0.121278,"preClose":16.12,"low":16.03,"week52Low":11,"pbRate":"4.98","psRate":"85.77","week52High":18.18,"institutionHeld":0,"latestPrice":17.72,"committee":-0.183673,"eps":-3.27625,"divideRate":0,"volume":2500128,"delay":0,"ttmEps":-3.27625,"open":16.67,"prevYearClose":16,"prevWeekClose":16.12,"prevMonthClose":14,"prevQuarterClose":16.87,"fiveDayClose":15.69,"twentyDayClose":13.68,"sixtyDayClose":13.09},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GENB\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-06","symbol":"GENB","fiscalQuarterEnding":"2026/06","expectedEps":-0.48,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1785988800000,"reportTimeType":"pre","actualEps":-0.52},{"market":"US","date":"2026-05-07","symbol":"GENB","fiscalQuarterEnding":"2026/03","expectedEps":-0.48,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778126400000,"reportTimeType":"pre","actualEps":-1.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GENB\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GENB\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.1667,"buy":0.8333,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.8333,"analysts":6,"updateTime":1782360000000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/GENB\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"GENB","date":"2026-08-21","current":-4.920259,"percent":0.191667,"low":-10.037721,"twenty":-8.626167,"median":-7.947085,"eighty":-7.52196,"high":-6.883628,"avg":-8.104092,"sd":0.705945,"marketCap":2052355451},"quantilePoints":[{"date":"2026-02-27","current":-10.037721,"twenty":-10.037721,"median":-10.037721,"eighty":-10.037721,"marketCap":2039203216},{"date":"2026-03-06","current":-7.810602,"twenty":-7.936073,"median":-7.722772,"eighty":-7.484376,"marketCap":1586755002},{"date":"2026-03-13","current":-8.331309,"twenty":-7.979988,"median":-7.660036,"eighty":-7.484376,"marketCap":1692538669},{"date":"2026-03-20","current":-7.710225,"twenty":-7.979988,"median":-7.68513,"eighty":-7.484376,"marketCap":1566362970},{"date":"2026-03-27","current":-8.061545,"twenty":-7.979988,"median":-7.697677,"eighty":-7.484376,"marketCap":1637735082},{"date":"2026-04-02","current":-8.350129,"twenty":-7.996299,"median":-7.697677,"eighty":-7.419131,"marketCap":1696362175},{"date":"2026-04-10","current":-7.233433,"twenty":-7.996299,"median":-7.647489,"eighty":-7.419131,"marketCap":1469500817},{"date":"2026-04-17","current":-7.910979,"twenty":-8.036451,"median":-7.697677,"eighty":-7.419131,"marketCap":1607147034},{"date":"2026-04-24","current":-8.067818,"twenty":-8.0628,"median":-7.732183,"eighty":-7.42164,"marketCap":1639009584},{"date":"2026-05-01","current":-7.923526,"twenty":-8.036451,"median":-7.810602,"eighty":-7.471829,"marketCap":1609696038},{"date":"2026-05-08","current":-8.522653,"twenty":-8.180743,"median":-7.816876,"eighty":-7.489394,"marketCap":1731410980},{"date":"2026-05-15","current":-8.844872,"twenty":-8.266063,"median":-7.84197,"eighty":-7.500687,"marketCap":1971654609},{"date":"2026-05-22","current":-8.039526,"twenty":-8.266063,"median":-7.83256,"eighty":-7.486839,"marketCap":1792130926},{"date":"2026-05-29","current":-7.527711,"twenty":-8.282375,"median":-7.816876,"eighty":-7.489371,"marketCap":1678039615},{"date":"2026-06-05","current":-8.453579,"twenty":-8.282375,"median":-7.810602,"eighty":-7.474106,"marketCap":1884429514},{"date":"2026-06-12","current":-7.435699,"twenty":-8.229473,"median":-7.788352,"eighty":-7.435629,"marketCap":1657528818},{"date":"2026-06-18","current":-7.976268,"twenty":-8.211907,"median":-7.788092,"eighty":-7.435594,"marketCap":1778029753},{"date":"2026-06-26","current":-9.442705,"twenty":-8.343203,"median":-7.810602,"eighty":-7.4449,"marketCap":2104920587},{"date":"2026-07-02","current":-9.488711,"twenty":-8.508838,"median":-7.810602,"eighty":-7.463837,"marketCap":2115175986},{"date":"2026-07-10","current":-9.040154,"twenty":-8.869967,"median":-7.84197,"eighty":-7.484992,"marketCap":2015185848},{"date":"2026-07-17","current":-7.855502,"twenty":-8.85402,"median":-7.855502,"eighty":-7.488094,"marketCap":1751109331},{"date":"2026-07-24","current":-7.953265,"twenty":-8.801131,"median":-7.883241,"eighty":-7.493159,"marketCap":1772902053},{"date":"2026-07-31","current":-8.06828,"twenty":-8.626167,"median":-7.861253,"eighty":-7.503197,"marketCap":1798540550},{"date":"2026-08-07","current":-7.489636,"twenty":-8.522653,"median":-7.910979,"eighty":-7.503197,"marketCap":1780593602},{"date":"2026-08-14","current":-8.114449,"twenty":-8.453579,"median":-7.917253,"eighty":-7.52196,"marketCap":1929137113},{"date":"2026-08-21","current":-8.632737,"twenty":-8.626167,"median":-7.947085,"eighty":-7.52196,"marketCap":2052355451}],"updateTime":1787571457218},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"GENB\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2621068889","title":"Generate Biomedicines initiated with a Buy at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2621068889","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621068889?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:15","pubTimestamp":1774343742,"startTime":"0","endTime":"0","summary":"Guggenheim initiated coverage of Generate Biomedicines (GENB) with a Buy rating and $30 price target The firm has “high conviction in multi-blockbu...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621050714","title":"Generate Biomedicines initiated with an Overweight at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2621050714","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621050714?lang=en_us&edition=fundamental","pubTime":"2026-03-24 17:00","pubTimestamp":1774342831,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst Edward Tenthoff initiated coverage of Generate Biomedicines (GENB) with an Overweight rating and $24 price target The company...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-an-overweight-at-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621575470","title":"Generate Biomedicines initiated with a Buy at Goldman Sachs","url":"https://stock-news.laohu8.com/highlight/detail?id=2621575470","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621575470?lang=en_us&edition=fundamental","pubTime":"2026-03-24 16:35","pubTimestamp":1774341311,"startTime":"0","endTime":"0","summary":"Goldman Sachs initiated coverage of Generate Biomedicines (GENB) with a Buy rating and $26 price target The company integrates generative AI models...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-initiated-with-a-buy-at-goldman-sachs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2237443465.HKD","LU2471134879.HKD","BK4588","LU1868836591.USD","BK4139","LU2471134523.USD","LU0345770308.USD","LU0061475181.USD","LU0742534661.SGD","LU2265009873.SGD","BK4551","BK4587","LU2237443382.USD","BK4550","LU0251131958.USD","LU1868836757.USD","IE00B19Z3581.USD","BK4516","BK4543","IE00BSNM7G36.USD","BK4585","LU1791807156.HKD","LU2237443622.USD","LU1868836914.USD","LU1868837300.USD","LU2471134796.USD","AIYY","LU2471134952.CNY","LU2750360641.GBP","LU2237443895.HKD","IE0004091025.USD","LU0251142724.SGD","LU2237443978.SGD","BK4127","LU2750360997.AUD","IE0002270589.USD","GSX","LU0345770993.USD","IE0034235188.USD","BK4504","BK4528","GENB","LU1668664300.SGD","AI","BK4023","IE0004086264.USD","LU0106831901.USD","LU2237438978.USD","IE00B19Z3B42.SGD","LU1894683348.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621000051","title":"Generate Biomedicines Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $24","url":"https://stock-news.laohu8.com/highlight/detail?id=2621000051","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621000051?lang=en_us&edition=fundamental","pubTime":"2026-03-24 15:43","pubTimestamp":1774338190,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nFWN40B0RB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621012051","title":"U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, Sunoco","url":"https://stock-news.laohu8.com/highlight/detail?id=2621012051","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621012051?lang=en_us&edition=fundamental","pubTime":"2026-03-24 15:39","pubTimestamp":1774337945,"startTime":"0","endTime":"0","summary":"U.S. RESEARCH ROUNDUP-Apogee Therapeutics, Insmed, SunocoMarch 24 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Apogee","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL4N40C0IK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SUN","VTRS","ACDC","LU0354030511.USD","APA","BK4189","LGND","SMCY","SMCZ","SRZN","KRYS","LU0690374961.EUR","SMCI","NCNO","ECL","CF","BK4515","CCL","T","WEC","SMCL","VZ","LW","REG","INSM","KMI","PFE","BK4165","ADM","MKC","CXW","BRX","BG","RLMD","BK4504","SPG","SMCX","GENB","RL","XNCR","DAR","NYT","TSN","FRT","DXCM","SMYY","APGE","STRO","LU0496365809.HKD","SMCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617538936","title":"Generate Biomedicines CEO Michael Nally Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2617538936","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617538936?lang=en_us&edition=fundamental","pubTime":"2026-03-07 05:56","pubTimestamp":1772834209,"startTime":"0","endTime":"0","summary":"Michael Nally, chief executive officer and director of Generate Biomedicines Inc., reported acquiring 20,000 shares of the company’s common stock. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 06, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260306:nNDL7rR47K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Generate Biomedicines CEO Michael Nally Acquires Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616636213","title":"Generate Biomedicines Director Jane L Mendillo Acquires Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2616636213","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616636213?lang=en_us&edition=fundamental","pubTime":"2026-03-03 06:48","pubTimestamp":1772491686,"startTime":"0","endTime":"0","summary":"Jane L Mendillo, a director of Generate Biomedicines Inc., reported an acquisition of 1,500 common shares. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 02, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL3FZcFV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616362984","title":"Noubar Afeyan, Director, Acquires Generate Biomedicines Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2616362984","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616362984?lang=en_us&edition=fundamental","pubTime":"2026-03-03 06:43","pubTimestamp":1772491420,"startTime":"0","endTime":"0","summary":"Noubar Afeyan, a director and 10% owner of Generate Biomedicines Inc., reported the acquisition of common shares. The filing also lists reporting beneficial owners including Flagship VentureLabs VI LLC, Flagship Pioneering Fund VI, L.P., Flagship Pioneering Fund VII, L.P., Nutritional Health LTP Fund, L.P., and other reporting beneficial owners. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 02, 2026, and is solely responsible for the information contain","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL8qZfyL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Noubar Afeyan, Director, Acquires Generate Biomedicines Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616364281","title":"Generate Biomedicines Adopts Amended and Restated Bylaws","url":"https://stock-news.laohu8.com/highlight/detail?id=2616364281","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616364281?lang=en_us&edition=fundamental","pubTime":"2026-03-03 06:22","pubTimestamp":1772490160,"startTime":"0","endTime":"0","summary":"Generate Biomedicines Inc. announced amended and restated bylaws that took effect with the effectiveness of its IPO registration statement. The changes establish procedures for stockholders to take formal actions at stockholder meetings, add an advance notice process for stockholder proposals and director nominations at annual meetings, and update the bylaws to align with the company’s amended and restated certificate of incorporation.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Generate Biomedicines Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 02, 2026, and is solely res","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260302:nNDL8gq2lY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616735468","title":"Opening Day: Generate Biomedicines makes public debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2616735468","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616735468?lang=en_us&edition=fundamental","pubTime":"2026-03-03 00:30","pubTimestamp":1772469040,"startTime":"0","endTime":"0","summary":"Generate Biomedicines made its public debut last week. The clinical‑stage company, which positions itself as a pioneer in AI‑driven drug design and...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/opening-day-generate-biomedicines-makes-public-debut-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/opening-day-generate-biomedicines-makes-public-debut-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","GENB","BK4528","AIYY","BK4551","BK4585","BK4587","BK4023","BK4543"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614143869","title":"Generate Biomedicines Shares Fall After Nasdaq Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=2614143869","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614143869?lang=en_us&edition=fundamental","pubTime":"2026-02-28 02:22","pubTimestamp":1772216575,"startTime":"0","endTime":"0","summary":"Generate Biomedicines (GENB) shares fell 15% to $13.67 in their Nasdaq debut on Friday after the company priced its initial public offering of 25 million shares at $16 each.The stock opened at $15 and fell as low as $13.47.Price: 13.67, Change: -2.33, Percent Change: -14.56","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB","NQmain"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192265905","title":"Stock Track | Generate Biomedicines Plummets 6.25% Intraday as Stock Debuts Below IPO Price","url":"https://stock-news.laohu8.com/highlight/detail?id=1192265905","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192265905?lang=en_us&edition=fundamental","pubTime":"2026-02-28 02:09","pubTimestamp":1772215784,"startTime":"0","endTime":"0","summary":"Generate Biomedicines (GENB) saw its stock plummet 6.25% during intraday trading on Friday, following its initial public offering.The decline came as the company's shares opened at $15 in their...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614186625","title":"Generate Biomedicines opens at $15.00, IPO priced at $16.00","url":"https://stock-news.laohu8.com/highlight/detail?id=2614186625","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614186625?lang=en_us&edition=fundamental","pubTime":"2026-02-28 01:55","pubTimestamp":1772214943,"startTime":"0","endTime":"0","summary":"Generate Biomedicines (GENB) priced 25M shares at $16.00. The deal priced at the midpoint of the $15.00-$17.00 target range. Goldman Sachs and Morg...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-opens-at-15-00-ipo-priced-at-16-00-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/generate-biomedicines-opens-at-15-00-ipo-priced-at-16-00-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BSNM7G36.USD","IE0002270589.USD","LU1804176565.USD","LU2237443465.HKD","IE0004086264.USD","BK4533","LU2237443895.HKD","LU0251142724.SGD","IE00B19Z3581.USD","LU0048573561.USD","BK4516","LU0061475181.USD","LU0096364046.USD","LU2471134523.USD","LU2471134952.CNY","IE0034235188.USD","LU0345770993.USD","IE00BFXG1179.USD","LU0345770308.USD","LU2237443978.SGD","LU2471134879.HKD","IE00B19Z3B42.SGD","LU2237443382.USD","BK4585","LU2237443622.USD","LU1668664300.SGD","LU2471134796.USD","BK4550","LU2237438978.USD","LU0251131958.USD","LU0742534661.SGD","LU1868836591.USD","BK4552","LU2750360997.AUD","LU1791807156.HKD","BK4588","LU0106831901.USD","GSX","LU1894683348.USD","LU1868837300.USD","LU1868837136.USD","LU2265009873.SGD","LU1868836757.USD","LU2237443549.SGD","BK4504","LU1868836914.USD","GENB","IE0004091025.USD","LU2750360641.GBP","BK4127"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614866608","title":"Shares of Generate Biomedicines Open at $15 in Their Nasdaq Debut VS $16 IPO Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2614866608","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614866608?lang=en_us&edition=fundamental","pubTime":"2026-02-28 01:51","pubTimestamp":1772214669,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL4N3ZN1R7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614853855","title":"BUZZ-Flagship-backed Generate Biomedicines set for Nasdaq debut after $400 million IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2614853855","media":"Reuters","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614853855?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:48","pubTimestamp":1772196503,"startTime":"0","endTime":"0","summary":"BUZZ-Flagship-backed Generate Biomedicines set for Nasdaq debut after $400 million IPO** Drug developer Generate Biomedicines GENB.O, backed by venture firm Flagship Pioneering, set to begin trading on Nasdaq later on Friday under ticker symbol \"GENB\"** GENB raised $400 million in its IPO by selling 25 million shares at $16 apiece, compared with the marketed range of $15 and $17 apiece** Founded in 2018 by Flagship, Generate's drug pipeline is focused on immunology and oncology** Generate's lead product candidate, GB-0895, to treat severe asthma is being tested in a late-stage trial, which is expected to be fully enrolled by the first half of 2028** \"Entering the market with a lead asset already in Phase 3 trials significantly de-risks the company, aligning with the current market trend where investors strongly favor biotech IPOs with advanced clinical assets over purely pre-clinical or early stage portfolios\", said IPOX Research Associate Lukas Muehlbauer** Goldman Sachs and Morgan St","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nL4N3ZN0Z9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2471134523.USD","LU0006306889.USD","LU0225283273.USD","LU0557290698.USD","LU2750360641.GBP","LU0912757837.SGD","BK4504","LU1548497426.USD","LU1989772923.USD","LU2471134796.USD","LU2750360997.AUD","LU1791710582.SGD","LU0106831901.USD","LU1894683348.USD","LU2347655156.SGD","LU1732800096.USD","LU1074936037.SGD","LU2237443382.USD","IE00BKVL7J92.USD","LU0267386448.USD","LU2357305700.SGD","LU1244550577.SGD","LU0096364046.USD","LU2089283258.USD","BK4127","BK4585","IE00BFXG1179.USD","GSX","IE0034235188.USD","LU0314104364.USD","LU1868837300.USD","LU0098860793.USD","LU0320765646.SGD","BK4588","LU0795875169.SGD","LU1791807156.HKD","LU2133065610.SGD","LU2471134952.CNY","LU1791710400.SGD","LU0971096721.USD","BK4516","LU1244550494.USD","BK4550","LU0158827948.USD","LU2023251221.USD","LU1868836757.USD","LU1668664300.SGD","IE00B19Z3B42.SGD","LU1162221912.USD","GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614901834","title":"Generate Biomedicines Prices $400 Million Initial Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2614901834","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614901834?lang=en_us&edition=fundamental","pubTime":"2026-02-27 18:32","pubTimestamp":1772188340,"startTime":"0","endTime":"0","summary":"Generate Biomedicines , a clinical-stage generative biology firm, said late Thursday it priced its initial public offering of 25 million common shares at $16 each.IPO underwriters have a 30-day overallotment option to purchase up to 3.75 million additional shares.The company expects its shares to start trading on the Nasdaq Global Select Market under the ticker symbol GENB Friday, while the IPO is expected to close Monday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614333588","title":"NASDAQ TRADE HALT  REASON NOT AVAILABLE AT 04:00 AM","url":"https://stock-news.laohu8.com/highlight/detail?id=2614333588","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614333588?lang=en_us&edition=fundamental","pubTime":"2026-02-27 17:00","pubTimestamp":1772182802,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALT  REASON NOT AVAILABLE AT 04:00 AM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260227:nAQN2LO0RZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GENB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161532521","title":"AI Biotech Firm Generate Biomedicines Sets IPO at $16 Per Share for Nasdaq Debut","url":"https://stock-news.laohu8.com/highlight/detail?id=1161532521","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161532521?lang=en_us&edition=fundamental","pubTime":"2026-02-27 15:01","pubTimestamp":1772175675,"startTime":"0","endTime":"0","summary":"Generate Biomedicines (GENB.US), an AI-driven drug discovery company focused on immunology and oncology, has finalized its U.S. IPO pricing. The clinical-stage biotech firm, which is advancing...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QQQJ","QLD","TSYW.SI","NVIW.SI","BK1147","USAW.SI","SQQQ","GENB","MNQmain","USJW.SI","QQQY","BK4007","GPIQ","QQQM","JEPQ","QYLD","QYLG","QID","PSQ","QQQE","QQQ","TQQQ","BK1191","BK1574"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2614788589","title":"U.S. Biotech Firm Generate Biomedicines Raises $400 Mln in IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2614788589","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614788589?lang=en_us&edition=fundamental","pubTime":"2026-02-27 13:44","pubTimestamp":1772171040,"startTime":"0","endTime":"0","summary":"Generate Biomedicines has announced the pricing of its initial public offering, implying a market value of about $2 billion for the U.S. biotechnology firm.The company, which specializes in designing and developing drugs using artificial intelligence, raised $400 million from selling 25 million shares at $16.00 each.Shares are expected to start trading on Friday, with the public offering set to close on March 2.Generate has granted underwriters a 30-day option to purchase up to an additional 3.75 million shares.In September, the Somerville, Mass.-based company said it had raised nearly $700 million in equity financing since 2020, including $273 million from a Series C funding round backed by investors such as Nvidia's venture capital arm.Goldman Sachs and Morgan Stanley are acting as joint lead book-running managers for the IPO.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225283273.USD","LU1244550577.SGD","BK4127","BK4534","LU1720051108.HKD","LU0158827781.USD","LU0528227936.USD","LABU","LU0098860793.USD","LU2089284900.SGD","LU1162221912.USD","LU0106261372.USD","LU0882574139.USD","LU2357305700.SGD","LU0158827948.USD","LU0267386448.USD","GENB","LU0314104364.USD","LU1244550494.USD","LU1668664300.SGD","LU0234570918.USD","LU0795875086.SGD","BK4581","LU0971096721.USD","LU1074936037.SGD","BK4585","LU1244550221.USD","LU0557290698.USD","LU1548497426.USD","LU2271345857.HKD","IE00BKVL7J92.USD","BK4516","LU0795875169.SGD","LU2089283258.USD","BK4588","LU0912757837.SGD","LU1732799900.SGD","LU1791710400.SGD","LU1363072403.SGD","LU2023251221.USD","LU2028103732.USD","LU1989772840.SGD","LU0106831901.USD","LU1791710582.SGD","LU1989772923.USD","IE00BZ1G4Q59.USD","BK4504","LU2111349929.HKD","LU1720051017.SGD","LU0006306889.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":59,"code":"91000000","status":"200"}]}}